Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.

Trial Details

NCT ID

NCT07764978

Phase

PHASE3

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

AZD0120
Daratumumab
Dexamethasone
Isatuximab
Lenalidomide
Bortezomib

Locations (sample)

Gilbert, Arizona, United States|33.35283,-111.78903
Orange, California, United States|33.78779,-117.85311
Aurora, Colorado, United States|39.72943,-104.83192
New Haven, Connecticut, United States|41.30815,-72.92816
Coral Gables, Florida, United States|25.72149,-80.26838

Key Eligibility Criteria

Participants must be 18 years or older, at the time of signing the ICF.
Participant must have documented diagnosis of MM according to the IMWG diagnostic criteria.
Participant must have one or more of the following measurable disease criteria: (a) Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 20…
Participant must be deemed ineligible for ASCT while also having adequate organ function for CAR-T cell treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →